Adamax vs CJC-1295
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Adamax is a synthetic neuropeptide related to brain-derived neurotrophic factor (BDNF) signaling pathways. It is explored for cognitive enhancement, neuroprotection, and mood support, with proposed mechanisms involving TrkB receptor activation and enhancement of neuroplasticity similar to endogenous BDNF.
- CJC-1295 is a synthetic GHRH analog that stimulates the pituitary gland to produce and release growth hormone. The DAC (Drug Affinity Complex) version has a markedly extended half-life. The No DAC version (Modified GRF 1-29) preserves natural pulsatile GH release and is preferred in most protocols.
- Half-Life
- Estimated 1-3 hours (short; peptide degradation)
- ~30 minutes (No DAC) / 6–8 days (with DAC)
- Admin Route
- Subcutaneous, Intranasal (research)
- SubQ
- Research
- —
- —
- Typical Dose
- 200-400 mcg per dose
- 100 mcg
- Frequency
- Once daily or every other day
- Once daily, before bed
- Key Benefits
- Proposed enhancement of learning and memory consolidation
- Neuroprotective via BDNF-TrkB pathway support
- May improve mood and resilience to stress
- Potential support for neurogenesis
- Cognitive clarity and focus enhancement (reported anecdotally)
- Explored for neurodegeneration and age-related cognitive decline
- Sustained increase in growth hormone levels
- Enhanced muscle growth and strength
- Improved fat metabolism and body composition
- Better recovery and tissue repair
- Increased bone density
- Enhanced immune function
- Improved skin quality and collagen production
- Synergistic GH release when combined with GHRPs like Ipamorelin
- Side Effects
- Limited human safety data; largely anecdotal reports
- Possible headache or mild overstimulation
- Sleep disruption with late-day dosing
- Unknown long-term safety profile
- Water retention / puffiness
- Carpal tunnel syndrome (with prolonged use)
- Injection site irritation
- Hunger increase (minor)
- +1 more
- Stacks With
- —
- —